High-throughput drug screening identifies AGR2 as a therapeutic target in clear cell ovarian cancer, suggesting vulnerability to proteasome inhibitors and dinaciclib.
Immunoblot analysis of AGR2-knockout 18-015 organoid showing no upregulation of SLFN11
No takes yet. Share an insight, caveat, or question.
Yoshimura et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: